GIP: Glucose-dependent Insulinotropic Peptide

Completed · Phase 1

Conditions studied: Type 2 Diabetes

In brief

The purpose of this study is to test the safety of glucose-dependent insulinotropic peptide (GIP)/GIP Analog on people with Type 2 Diabetes.

Key facts

Study ID

NCT00239707

Run by

National Institute on Aging (NIA)

People needed

41

Starts

2003-02-01

Expected to finish

2006-12-01

Last updated by the study team

2013-11-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age and older
• Healthy Type 2 Diabetics
• Agree to stay off glucosidases for 3 days prior to infusion visits (Examples: Precose, Glyset)
• Agree to stay off Sulfonylureas 5 days prior to infusion visits (Examples: Glucotrol, Amaryl, glyburide, metformin
• Able to ingest 1000 mg Tylenol on study visits
• Able to consume study breakfast consisting of scrambled egg, white toast with margarine, corn flakes, 2% milk, banana at each infusion visit
• Female participants must have Hct > 36
• Male participant must have Hct > 38
• No kidney or liver disease per history and evidenced by blood and urine tests
• Physical Exam and EKG that do not contraindicate patient to be in the study

You may not qualify if…

• Taking the following medications: Insulin, or Thiazolidinediones, i.e. Avandia, Actos
• Pregnancy
• Steroid use within the past 3 months
• Recent infection, fever or chills

Where it is running

• National Institute on Aging, Clinical Research Branch — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.